Recent Reports


2010-01-25: Medical Research, Diagnostic Substances, Life Science Tools Report
7 leading Analysts; and top management from 2 Sector Firms examine this vital industry in this 38 page report from The Wall Street Transcript.
More Information
Order this Report

2009-12-07: Consumer Health Services Report
7 leading Analysts; and top management from 2 Sector Firm examine this vital industry in this 53 page report from The Wall Street Transcript.
More Information
Order this Report

2009-11-02: Pharmaceuticals Report
3 leading Analysts; and top management from 16 Sector Firms examine this vital industry in this 76 page report from The Wall Street Transcript.
More Information
Order this Report

2009-10-19: Biotechnology Report
3 leading Analysts; 2 Money Managers; and top management from 12 Sector Firms examine this vital industry in this 70 page report from The Wall Street Transcript.
More Information
Order this Report

09.21.09: Medical Real Estate: Healthcare REITs, Long-Term Care Facilities & Hospitals Report
3 analysts and 6 sector firms examine the medical real estate segment in this 45 page report from The Wall Street Transcript.
More Information
Order this Report

09.21.09: Medical Devices Report
4 analysts and 7 sector firms examine the medical devices segment in this 41 page report from The Wall Street Transcript.
More Information
Order this Report

09.14.09: Medical Research Services Report
2 analysts, and 4 sector firms examine the medical research services segment in this 23 page report from The Wall Street Transcript.
More Information
Order this Report

Search TWST Online

TWST Newsletter

Give us your email address and receive the TWST Newsletter.


Company Interview Excerpt
Novelos Therapeutics, Inc. - Harry Palmin


Full article published: 10/19/2009


For Subscribers

Get this article online now!

Order just this article
TWST: Please give us a history of Novelos Therapeutics.
Mr. Palmin: Novelos was formed back in 1996 to commercialize a novel oxidized glutathione-based platform technology. We went public in 2005, and we've raised, I'm pleased to say, over 70 million to date through institutional financings and partnerships. So we've taken a technology from a proof of concept through pivotal Phase III trial, and this trial is expected to read out early next year.

TWST: Tell us about your technology. What are oxidized glutathione-based compounds and what are their applications?
Mr. Palmin: The primary application is cancer. We have a unique and revolutionary approach with our lead compound, NOV-002. One, it potentiates chemotherapy, making it work better with better survival and better anti-tumor effects than chemotherapy alone while, two, helping the patients recover from the toxicities of chemotherapy. And three, NOV-002 itself is safe. So we are not adding any toxicity. We have potentiation, recovery and safety. Scientifically speaking, we regulate redox-sensitive cell signaling pathways that are involved in cancer proliferation, cell-mediated immunity and hematopoiesis. And all of our publications, including peer-reviewed, are available on our Web site, www.novelos.com, at the NOV-002 section.

 

Tickers included in this excerpt: NVLT.OB

 

For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.